MeiraGTx Holdings plc announced the appointment of Robert K. Zeldin, M.D. as chief medical officer (CMO). A clinical immunologist by training, Dr. Zeldin brings more than 20 years of clinical, regulatory and industry experience to MeiraGTx, ranging from early-stage clinical development through Biologics License Application (BLA) filing and commercialization. Prior to joining MeiraGTx, Dr. Zeldin was CMO of Immunovant.